<DOC>
	<DOCNO>NCT00226798</DOCNO>
	<brief_summary>Immunochemotherapy consist IL-2 , INF-A , VBL 5FU regard treatment choice metastatic renal cell carcinoma . During period 1996-2000 , evaluate efficacy toxicity immunochemotherapy , combine aggressive surgical approach : nephrectomy treatment resection residual disease . The 3-year survival rate entire group complete responder patient 30 % 88 % , respectively . The side effect usually moderate consist mainly flu-like syndrome , headache , nausea , vomit depression . Most importantly , drug-related death . Good performance status , absence bone metastases prior nephrectomy associate high response rate . Capecitabine novel fluoropyrimidine carbamate , orally administer selectively activate Fluorouracil sequential triple-enzyme pathway liver tumor cell . Capecitabine dose 2,500mg/m2/d divide equally two daily dos 14 day patient fail respond “ standard ” immunotherapy achieve 30 % objective response . Toxicity consist hand-foot syndrome . Aim Study : To evaluate efficacy toxicity combination IL-2 , INF-A , VBL Capecitabine MRCC</brief_summary>
	<brief_title>Immunochemotherapy Metastatic Renal Cell Carcinoma</brief_title>
	<detailed_description>This phase II study , non-randomized patient metastatic renal cell carcinoma . The treatment include : Proleukin ( produce Chiron supply Megapharm Israel Ltd ) , Roferon A Xeloda ( produce Roche ) VBL . The treatment give 8-week course interval two week rest response ( D63 ) toxicity assess . 45 patient MRCC enter study 18-month period . All patient must meet inclusion exclusion criterion . All data participate patient , include medical history , disease characteristic , laboratory imaging test , response toxicity treatment enter specific form , , treatment course follow . Patients follow survival status disease status every 6 month last visit death . Treatment Schedule : Proleukin S.C. 10X106 IU/m2 three time week ( Sun , Tue , Thu ) , week 1 – 4 Roferon A S.C. 6 X 106 IU/m2 week ( Wed ) , week 1 – 4 Roferon A S.C. 3 X 106 IU/m2 three time week , week 5 – 8 Xeloda Oral 1,000 mg/m2 twice day , week 5 , 6 Vinblastine I.V . 4mg/m2 , Day 1 , week 5 &amp;</detailed_description>
	<mesh_term>Adenocarcinoma</mesh_term>
	<mesh_term>Carcinoma , Renal Cell</mesh_term>
	<mesh_term>Adenocarcinoma , Clear Cell</mesh_term>
	<mesh_term>Capecitabine</mesh_term>
	<criteria>Inclusion Criteria ; Patients follow criterion include study Pathological ( histology cytology ) diagnosis renal cell carcinoma Clinical evidence metastatic disease Performance status 0 – 2 ( European Cooperative Oncology Group Score ) Nephrectomy start treatment Normal cardiac function ( left ventricular ejection fraction &gt; 45 % ) . Normal blood count : WBC &gt; 3,000/ml3 , Hb &gt; 10gr % , Platelets &gt; 100,000/ml3 Normal kidney function : Creatinine &lt; 1.3 mg/dl Age  18 year Patient ’ write consent ( informed consent form ) Life expectancy le 3 month Brain metastasis Ischemic heart disease – active Prior immunochemotherapy Performance status 3 ( European Cooperative Oncology Group Score ) Schizophrenia Active liver disease</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>September 2005</verification_date>
</DOC>